CRON — Cronos Group Inc. · 2026-09-05 · Verdict: WATCH · Conviction 2
Price $3.26 (screen row, universe_under2b.csv regenerated 2026-09-05; no live prices available) · Mkt cap $1.21B (370,726,047 shares at 2026-06-30) · EV ~$382M ex-NCI · EV/LTM adj EBITDA 17.7x, 8.2x on annualized Q2 · Net cash $827.0M · ADV $4.6M Sources read: 10-K 2026-02-26 (Items 1, 1A, 7), 10-Q 2026-08-06, DEF 14A 2026-04-24, 8-Ks 2026-05-11 (Q1 results, SPA amendment), 2026-06-22, 2026-08-06 (Q2 results), 2026-08-07, Form 4s (12m). No transcript in the bundle.
1. What the business actually does
Cronos sells branded cannabis in three places (10-K 2025, Item 1). In Canada, adult-use flower, vapes and edibles under Spinach and Lord Jones through provincial boards. In Israel, medical cannabis through pharmacies via Cronos Israel, a joint venture with Kibbutz Gan Shmuel in which Cronos holds 70% of the cultivation company and 90% of the other three. Elsewhere (Germany, the UK, Australia, Switzerland, Malta) it exports PEACE NATURALS and LIT flower through distributors. Supply comes mainly from Cronos GrowCo, a 50%-owned Ontario greenhouse consolidated since Cronos took board control on 2024-07-01. One segment, no US Schedule I activity.
2. Why it is mispriced — the edge case
There is none. The screen row shows the stock 8.2% below its 52-week high, up 22.8% on 12-1 momentum and 26.8% over six months, on $4.6M of daily volume. No spin, no index deletion, no forced seller, and the "hidden asset" is a cash balance the company prints in the first table of its own earnings release.
What is wrong is the screen, in the company's favour. It counted only $467.0M of cash and flagged "debt data missing (net cash unverified)". The Q2 balance sheet resolves both: cash $467.0M plus short-term investments $330.0M plus non-current deposits $30.0M is $827.0M, against total liabilities of $62.4M containing no borrowings, the only debt-like item being a $1.3M lease obligation (8-K 2026-08-06). Real EV is about $382M, not $734M: a data correction anyone opening the filing has, not a mispricing, so the verdict is capped at WATCH.
3. Unit economics and growth
The inflection is real. Revenue went $87.2M (2023), $117.6M (2024), $146.6M (2025), at gross margins of 14%, 21%, 43% (Item 7). Q1 2026 was $45.2M, up 40% (30% constant currency), 42% margin, $5.1M adjusted EBITDA (8-K 2026-05-11); Q2 was $53.0M, up 58% (51% constant currency), 54% margin, $13.1M adjusted EBITDA and $7.4M of GAAP operating income (8-K 2026-08-06).
The margin jump has one stated cause: a mix shift to Israel and other countries, "which carry no excise taxes," plus fixed-cost absorption (8-K 2026-08-06). Q2 revenue was Canada $28.7M (+50%), Israel $15.0M (+60%), other countries $9.3M (+88%); Israel grew 32% on constant currency, so roughly half that headline is the shekel (10-Q).
Cash conversion is thinner than adjusted EBITDA implies. H1 operating cash flow was $34.9M, of which $21.8M is interest received on the cash pile; the business itself generated about $13.1M before $3.8M of capex. Capex is low because the GrowCo expansion is complete ($25.7M in 2025 against $3.8M in H1 2026), so the screen's 0.01% FCF yield is stale rather than structural. Minorities take a real slice: NCI earned $5.5M in H1 and was paid $3.7M of dividends.
4. Balance sheet and capital allocation
Debt-free, with net cash 68% of the market capitalisation, but interest income is decaying with rates: $52.0M (2024), $40.0M (2025), $17.7M in H1 2026 (Item 7; 10-Q). Buybacks are modest against the pile: 12,253,870 shares for $32.9M in H1 at roughly $2.68, taking shares from 381.6M to 370.7M, with $42.1M left under the 2026-05-08 authorisation, and Canadian NCIB rules cap the program at 5% of shares a year (10-Q).
Altria owns 41.6% (156,573,537 shares at 2026-03-31), holds four of seven board seats, has approval rights over certain actions above 10% and top-up rights above 20% (DEF 14A); Item 1A concedes the block "may impact the liquidity of our common shares." Insiders bought nothing in the open market in twelve months: 33 Form 4 rows, all grants, vestings and tax withholding, zero P or S codes, including none at $2.54 in March and May. Long-term pay is time-vesting RSUs with no performance shares (DEF 14A).
5. Management: what they said vs what they did
Gorenstein said on 2026-08-06 that repurchases "represent an attractive use of capital" and the company is "well positioned to invest in our growth strategy while returning capital to shareholders." The operating half checks out: two record quarters, ten straight records in Israel, Spinach number one in Canadian vapes and edibles. The capital half only partly: $32.9M of buybacks against $827M of cash, and no completed acquisition since CanAdelaar was signed 2025-12-09, its long stop date already pushed from 2026-06-09 to 2026-09-09 (10-Q). Cronos issues no guidance, so there is no prior forecast to score.
6. Valuation
Base (55%): 2027 revenue near $250M at a 22% adjusted EBITDA margin (between H1's 18.5% and Q2's 24.7%) is $55M, about $44M after minorities; at 9-10x that is $400-440M plus roughly $815M of net cash, on about 360M shares, or $3.40-3.50. Bear (25%): an Israeli duty lands, Israeli volume halves, margin reverts toward 43%; 2027 adjusted EBITDA near $20M, $16M attributable at 7x is $112M, with a 10% holding-company discount on the cash for Altria's veto rights: about $2.30. Bull (20%): no duty, Germany and the Netherlands scale; 2027 revenue $290M at 26% is $75M, $60M attributable at 12x is $720M plus $800M cash: about $4.25. Probability-weighted $3.35, roughly 3% above price. Reverse DCF: at $3.26 the market pays $382M for the operating business after netting cash. Against attributable owner earnings near $22M annualized (Q2 operating income $7.4M plus $3.4M depreciation less $1.8M capex, annualized, less about a quarter for minorities and modest cash tax) that is 17x, or at a 10% discount rate a price that implies about 4% perpetual growth from an already record quarter.
7. Catalysts and timeline
CanAdelaar long stop date 2026-09-09, four days out. The Israeli Trade Levies Commissioner's determination in the investigation opened 2026-08-05. Q3 results in early November, showing whether the 54% gross margin holds. Deployment of the $827M, or continued non-deployment.
8. Risks and pre-registered kill criteria
Israel dominates, and the record is dated. On 2025-04-10 the Minister of Economy approved a duty of up to 165% on Canadian cannabis imports, stopped only by the Finance Minister's veto on 2025-04-25, sustained by the Ministry of Justice on 2025-07-03, with a cultivators' petition dismissed 2025-12-18 (Item 1A). It then returned: a new investigation in June 2026, terminated on procedural grounds 2026-07-28, a fresh complaint 2026-07-30, a prima facie finding of dumping, injury and causation 2026-08-02, and a new investigation opened against the Company 2026-08-05 (8-K 2026-08-06). Israel is 28% of Q2 revenue and the highest-margin part of it.
Kill criteria: 1. A provisional or final anti-dumping duty is imposed on Canadian medical cannabis imports into Israel, or Israeli net revenue falls year over year for two consecutive quarters. 2. Consolidated gross margin below 45% for two consecutive quarters. 3. Cash, short-term investments and interest-bearing deposits below $750M without a closed acquisition or equivalent repurchases. 4. Shares outstanding above 375M.
9. Verdict and one-paragraph summary
WATCH, conviction 2. Cronos is genuinely debt-free with $827.0M of cash and investments, 68% of its market value, against total liabilities of $62.4M, and the screen understated that cash by $360M while wrongly flagging missing debt, so real enterprise value is about $382M rather than $734M. The operating turn is real: revenue $87.2M to $117.6M to $146.6M over three years, gross margin 14% to 21% to 43%, and a Q2 2026 printing $53.0M at a 54% margin with $13.1M of adjusted EBITDA against $1.7M a year earlier. But there is no edge case to underwrite: the stock sits 8.2% below its 52-week high after rising 27% in six months, nothing is forcing anyone to sell, and the correction that makes it look cheap is a data fix anyone reading the filing already has. Netting the cash, the market pays about 17x attributable owner earnings, implying roughly 4% perpetual growth from a record quarter, and probability-weighted value of $3.35 is 3% above price. Two facts hold it below IDEA. Israel is 28% of revenue and the margin engine, and an Israeli minister once already approved a duty of up to 165% on Canadian imports that only another ministry's veto stopped, with a fresh investigation opened 2026-08-05. And nobody with information is buying: not one open-market purchase across 33 insider transactions in twelve months, not even at $2.54, while $827M sits undeployed under a 41.6% holder with veto rights.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.